| Year |
Title |
Altmetric |
| 2023
|
A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings.
Arthritis and Rheumatology.
75:293-304.
2023
|
|
| 2023
|
Serum urate-lowering efficacy and safety of tigulixostat in gout patients with hyperuricemia: a randomized, double-blind, placebo-controlled, dose-finding trial (CLUE)..
Arthritis and Rheumatology.
2023
|
|
| 2022
|
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial.
Journal of Bone and Mineral Research.
37:2435-2442.
2022
|
|
| 2022
|
Satisfaction with modes of telemedicine delivery during COVID-19: A randomized, single-blind, parallel group, noninferiority trial.
American Journal of the Medical Sciences.
364:538-546.
2022
|
|
| 2022
|
Correction to: The clinician’s guide to prevention and treatment of osteoporosis (Osteoporosis International, (2022), 33, 10, (2049-2102), 10.1007/s00198-021-05900-y).
Osteoporosis International.
33:2243.
2022
|
|
| 2022
|
The clinician’s guide to prevention and treatment of osteoporosis.
Osteoporosis International.
33:2049-2102.
2022
|
|
| 2022
|
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial.
Arthritis and Rheumatology.
74:1593-1601.
2022
|
|
| 2022
|
Risk for osteoporosis and fracture with glucocorticoids.
Best Practice and Research: Clinical Rheumatology.
36.
2022
|
|
| 2022
|
COVID-19 vaccine uptake and vaccine hesitancy in rheumatic disease patients receiving immunomodulatory therapies in community practice settings.
Arthritis and Rheumatology.
74:1091-1092.
2022
|
|
| 2022
|
Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment.
Journal of Bone and Mineral Research.
37:1136-1146.
2022
|
|
| 2022
|
The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence.
Current Opinion in Rheumatology.
34:179-186.
2022
|
|
| 2022
|
The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids.
Arthritis and Rheumatology.
74:604-611.
2022
|
|
| 2022
|
Osteoporosis in 10 years time: a glimpse into the future of osteoporosis.
Therapeutic Advances in Musculoskeletal Disease.
14.
2022
|
|
| 2022
|
Development and Validation of an Emergency Department Electronic Medical Record Gout Flare Alert.
Arthritis Care and Research.
2022
|
|
| 2022
|
Racial and Sex Disparities in Gout Prevalence among US Adults.
JAMA Network Open.
E2226804.
2022
|
|
| 2022
|
Understanding Physicians’ Perceptions of Patient-Identified Barriers to Osteoporosis Medication Initiation: A Cognitive Mapping Approach.
Risk Management and Healthcare Policy.
15:1293-1302.
2022
|
|
| 2022
|
What’s new on the front-line of gout pharmacotherapy?.
Expert Opinion on Pharmacotherapy.
23:453-464.
2022
|
|
| 2021
|
Denosumab did not improve computerized tomography erosion scores when added to intensive urate-lowering therapy in gout: Results from a pilot randomized controlled trial.
Seminars in Arthritis and Rheumatism.
51:1218-1223.
2021
|
|
| 2021
|
Machine learning approaches for the prediction of bone mineral density by using genomic and phenotypic data of 5130 older men.
Scientific Reports.
11.
2021
|
|
| 2021
|
SToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout.
BMC Medicine.
19.
2021
|
|
| 2021
|
Serum urate as a proposed surrogate outcome measure in gout trials: From the OMERACT working group.
Seminars in Arthritis and Rheumatism.
51:1378-1385.
2021
|
|
| 2021
|
Variation in serum urate levels in the absence of gout and urate lowering therapy.
BMC Rheumatology.
5.
2021
|
|
| 2021
|
Higher Serum Urate Levels Are Associated With an Increased Risk for Sudden Cardiac Death.
Journal of Rheumatology.
48:1745-1753.
2021
|
|
| 2021
|
Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis.
Osteoporosis International.
32:1879-1888.
2021
|
|
| 2021
|
A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares.
Arthritis and Rheumatology.
73:1533-1542.
2021
|
|
| 2021
|
Disruptions in Rheumatology Care and the Rise of Telehealth in Response to the COVID-19 Pandemic in a Community Practice–Based Network.
Arthritis Care and Research.
73:1153-1161.
2021
|
|
| 2021
|
Effect of Serum Urate Lowering With Allopurinol on Blood Pressure in Young Adults: A Randomized, Controlled, Crossover Trial.
Arthritis and Rheumatology.
73:1514-1522.
2021
|
|
| 2021
|
Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Arthritis and Rheumatology.
73:1523-1532.
2021
|
|
| 2021
|
Use of path modeling to inform a clinical decision support application to encourage osteoporosis medication use.
Research in Social and Administrative Pharmacy.
17:1267-1275.
2021
|
|
| 2021
|
Designing a Strategy Trial for the Management of Gout: The Use of a Modified Delphi Panel.
ACR Open Rheumatology.
3:341-348.
2021
|
|
| 2021
|
Real-world bone turnover marker use: impact on treatment decisions and fracture.
Osteoporosis International.
32:831-840.
2021
|
|
| 2021
|
Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women’s Rheumatoid Arthritis Sequential Study Registry.
Arthritis Care and Research.
73:471-480.
2021
|
|
| 2021
|
Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis.
Journal of the American Academy of Dermatology.
84:1113-1119.
2021
|
|
| 2021
|
Correction to: Real-world bone turnover marker use: impact on treatment decisions and fracture (Osteoporosis International, (2020), 10.1007/s00198-020-05734-0).
Osteoporosis International.
32:609.
2021
|
|
| 2021
|
Reply.
Arthritis and Rheumatology.
73:548-549.
2021
|
|
| 2021
|
The Living Donor Navigator Program Provides Support Tools for Caregivers
2021
|
|
| 2021
|
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3.
Arthritis and Rheumatology.
73:e1-e12.
2021
|
|
| 2021
|
Flare rate thresholds for patient assessment of disease activity states in Gout.
Journal of Rheumatology.
48:293-298.
2021
|
|
| 2021
|
SARS CoV-2 infection among patients using immunomodulatory therapies.
Annals of the Rheumatic Diseases.
80:269-271.
2021
|
|
| 2021
|
Which factors predict discordance between a patient and physician on a gout flare?.
Rheumatology.
60:773-779.
2021
|
|
| 2021
|
Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region.
Journal of Clinical Densitometry.
24:3-13.
2021
|
|
| 2021
|
The Contribution of Patient, Primary Care Physician, and Primary Care Clinic Factors to Good Bone Health Care.
The Permanente Journal.
25:1-3.
2021
|
|
| 2020
|
Depressive Symptoms and the Effectiveness of a Urate-Lowering Therapy in a Clinical Trial.
ACR Open Rheumatology.
2:710-714.
2020
|
|
| 2020
|
Osteoporosis screening using computed tomography for men with prostate cancer: results of a prospective study.
Archives of Osteoporosis.
15.
2020
|
|
| 2020
|
Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Biology of Blood and Marrow Transplantation.
26:1784-1802.
2020
|
|
| 2020
|
Erratum to “Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture” [Clin Therapeut 42 (6) (2020) 1099–1107] (Clinical Therapeutics (2020) 42(6) (1099–1107.e1), (S0149291820301995), (10.1016/j.clinthera.2020.04.012))
2020
|
|
| 2020
|
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2.
Arthritis and Rheumatology.
72:e1-e12.
2020
|
|
| 2020
|
Cardiovascular safety risks associated with gout treatments.
Expert Opinion on Drug Safety.
19:1143-1154.
2020
|
|
| 2020
|
Physical activity measured using wearable activity tracking devices associated with gout flares.
Arthritis Research and Therapy.
22.
2020
|
|
| 2020
|
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1.
Arthritis and Rheumatology.
72:1241-1251.
2020
|
|
| 2020
|
Patient-centered outcomes and key study procedure finalization in the pilot feasibility gout randomized trial: Comparative feasibility study in GOUt, CHerry extract versus diet modification (Mini-GOUCH)
2020
|
|
| 2020
|
Racial Disparities Exist in Outcomes After Major Fragility Fractures.
Journal of the American Geriatrics Society.
68:1803-1810.
2020
|
|
| 2020
|
Efficacy of burosumab in a case of tumor-induced osteomalacia.
Revue du Rhumatisme.
87:300-302.
2020
|
|
| 2020
|
Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment.
Osteoporosis International.
31:1283-1290.
2020
|
|
| 2020
|
A Randomized Internet-Based Pilot Feasibility and Planning Study of Cherry Extract and Diet Modification in Gout
2020
|
|
| 2020
|
A Randomized Internet-Based Pilot Feasibility and Planning Study of Cherry Extract and Diet Modification in Gout.
2020
|
|
| 2020
|
Design, analysis, power, and sample size calculation for three-phase interrupted time series analysis in evaluation of health policy interventions.
Journal of Evaluation in Clinical Practice.
26:826-841.
2020
|
|
| 2020
|
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
Annals of the Rheumatic Diseases.
79:S685-S699.
2020
|
|
| 2020
|
Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture
2020
|
|
| 2020
|
Imminent Fracture Risk: A Call to Action for Rheumatologists.
Arthritis Care and Research.
72:741-743.
2020
|
|
| 2020
|
Allopurinol adherence and its predictors in gout: a national cohort study in US veterans.
Lancet Rheumatology.
2:e281-e291.
2020
|
|
| 2020
|
Duration of Bisphosphonate Drug Holidays and Associated Fracture Risk.
Medical Care.
58:419-426.
2020
|
|
| 2020
|
Reply to Serious Adverse Events With Romosozumab Use in Japanese Patients: Need for Clear Formulation of Contraindications Worldwide.
Journal of Bone and Mineral Research.
35:996-997.
2020
|
|
| 2020
|
Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition.
Orthopaedic Nursing.
39:145-161.
2020
|
|
| 2020
|
Gout is associated with an increased risk for incident heart failure among older adults: The REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study.
Arthritis Research and Therapy.
22.
2020
|
|
| 2020
|
Correction to: Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures (Osteoporosis International, (2020), 31, 1, (1-12), 10.1007/s00198-019-05176-3).
Osteoporosis International.
31:797-798.
2020
|
|
| 2020
|
Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort study.
Seminars in Arthritis and Rheumatism.
50:228-236.
2020
|
|
| 2020
|
Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition.
Journal of Orthopaedic Trauma.
34:E125-E141.
2020
|
|
| 2020
|
Comorbidities in gout and hyperuricemia: Causality or epiphenomena?.
Current Opinion in Rheumatology.
32:126-133.
2020
|
|
| 2020
|
Factors influencing the effectiveness of allopurinol in achieving and sustaining target serum urate in a US Veterans Affairs gout cohort.
Journal of Rheumatology.
47:449-460.
2020
|
|
| 2020
|
Simulation-based power and sample size calculation for designing interrupted time series analyses of count outcomes in evaluation of health policy interventions.
Contemporary Clinical Trials Communications.
17.
2020
|
|
| 2020
|
Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and Restart.
Journal of Bone and Mineral Research.
35:478-487.
2020
|
|
| 2020
|
Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures.
Osteoporosis International.
31:1-12.
2020
|
|
| 2020
|
Burosumab in tumor-induced osteomalacia: A case report.
Joint Bone Spine.
87:81-83.
2020
|
|
| 2020
|
Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition.
Journal of Bone and Mineral Research.
35:36-52.
2020
|
|
| 2020
|
Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort Study.
Hypertension.
75:246-256.
2020
|
|
| 2019
|
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
Lancet Diabetes and Endocrinology.
7:899-911.
2019
|
|
| 2019
|
Pragmatic Clinical Trials in Osteoporosis.
Current Osteoporosis Reports.
17:521-526.
2019
|
|
| 2019
|
Association of Early Postoperative Pain Trajectories with Longer-term Pain Outcome after Primary Total Knee Arthroplasty.
JAMA Network Open.
2.
2019
|
|
| 2019
|
Reply.
Arthritis and Rheumatology.
71:1771-1772.
2019
|
|
| 2019
|
Reply..
Arthritis and Rheumatology.
71:1771-1772.
2019
|
|
| 2019
|
Characteristics of older adults using patient web portals to view their DXA results.
BMC Medical Informatics and Decision Making.
19.
2019
|
|
| 2019
|
Race Plays a Role in the Knowledge, Attitudes, and Beliefs of Women with Osteoporosis.
Journal of Racial and Ethnic Health Disparities.
6:707-718.
2019
|
|
| 2019
|
A Qualitative Study of the Postoperative Pain Management Educational Needs of Total Joint Replacement Patients.
Pain Management Nursing.
20:345-351.
2019
|
|
| 2019
|
Long-Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five-Year Observational Study.
Arthritis Care and Research.
71:993-1003.
2019
|
|
| 2019
|
Vascular Consequences of Hyperuricemia and Hypouricemia.
Rheumatic Disease Clinics of North America.
45:453-464.
2019
|
|
| 2019
|
Cost-Effectiveness of Osteoporosis Screening Using Biomechanical Computed Tomography for Patients With a Previous Abdominal CT.
Journal of Bone and Mineral Research.
34:1229-1239.
2019
|
|
| 2019
|
Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four–Month Randomized, Double-Blind, Double-Dummy Trial.
Arthritis and Rheumatology.
71:1174-1184.
2019
|
|
| 2019
|
Osteoporosis Pathophysiology, Epidemiology, and Screening in Rheumatoid Arthritis.
Current Rheumatology Reports.
21.
2019
|
|
| 2019
|
Comparison of an interactive voice response system and smartphone application in the identification of gout flares.
Arthritis Research and Therapy.
21.
2019
|
|
| 2019
|
Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women.
Bone.
123:191-195.
2019
|
|
| 2019
|
Glucocorticoid-induced osteoporosis: 2019 concise clinical review.
Osteoporosis International.
30:1145-1156.
2019
|
|
| 2019
|
Changing rates in fracture trends are temporally associated with declining testing and treatment: reality or ecologic fallacy?.
Current Opinion in Rheumatology.
31:316-320.
2019
|
|
| 2019
|
Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial.
PLoS Medicine.
16.
2019
|
|
| 2019
|
Sex differences in osteoporosis self-efficacy among community-residing older adults presenting for DXA.
Osteoporosis International.
30:1033-1041.
2019
|
|
| 2019
|
Tools and Methods for Real-World Evidence Generation: Pragmatic Trials, Electronic Consent, and Data Linkages.
Rheumatic Disease Clinics of North America.
45:275-289.
2019
|
|
| 2019
|
Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial.
American Journal of Medicine.
132:354-361.
2019
|
|
| 2019
|
Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout.
Arthritis Care and Research.
71:427-434.
2019
|
|
| 2019
|
Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies.
Calcified Tissue International.
104:193-200.
2019
|
|
| 2019
|
Come from away: Best practices in mini-sabbaticals for the development of young investigators: a White Paper by the SEQUIN (mini-Sabbatical Evaluation and QUality ImprovemeNt) Group..
Journal of Clinical and Translational Science.
3:37-44.
2019
|
|
| 2019
|
Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts’ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation.
Osteoporosis International.
30:45-57.
2019
|
|
| 2019
|
Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy..
Core Evidence.
14:41-50.
2019
|
|
| 2019
|
Balancing benefits and risks in the era of biologics.
Therapeutic Advances in Musculoskeletal Disease.
11.
2019
|
|
| 2019
|
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.
Arthritis and Rheumatology.
71:143-153.
2019
|
|
| 2019
|
Glucocorticoid-induced osteoporosis update.
Current Opinion in Rheumatology.
31:388-393.
2019
|
|
| 2019
|
Glucocorticoid-induced osteoporosis: from clinical trials to clinical practice.
Therapeutic Advances in Musculoskeletal Disease.
11.
2019
|
|
| 2019
|
Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout.
Rheumatology.
58:61-69.
2019
|
|
| 2019
|
Is there a role for cherries in the management of gout?.
Therapeutic Advances in Musculoskeletal Disease.
11.
2019
|
|
| 2018
|
Diet and exercise changes following bone densitometry in the Patient Activation After DXA Result Notification (PAADRN) study.
Archives of Osteoporosis.
13.
2018
|
|
| 2018
|
Importance of Recent Fracture as Predictor of Imminent Fracture Risk.
Current Osteoporosis Reports.
16:738-745.
2018
|
|
| 2018
|
Medical Rehabilitation: Guidelines to Advance the Field With High-Impact Clinical Trials.
Archives of Physical Medicine and Rehabilitation.
99:2637-2648.
2018
|
|
| 2018
|
The prevalence of overtreatment of osteoporosis: results from the PAADRN trial.
Archives of Osteoporosis.
13.
2018
|
|
| 2018
|
Correction to: Hip fracture trends in the United States, 2002 to 2015 (Osteoporosis International, (2018), 29, 3, (717-722), 10.1007/s00198-017-4345-0).
Osteoporosis International.
29:2583.
2018
|
|
| 2018
|
How to use bisphosphonates safely and optimally.
Rheumatology.
57:1875-1876.
2018
|
|
| 2018
|
Is Rheumatoid Arthritis a Cardiovascular Risk-Equivalent to Diabetes Mellitus?.
Arthritis Care and Research.
70:1694-1699.
2018
|
|
| 2018
|
Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies.
Bone.
116:58-66.
2018
|
|
| 2018
|
Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions.
Journal of Bone and Mineral Research.
33:1881-1888.
2018
|
|
| 2018
|
Opioids vs nonopioids for chronic back, hip, or knee pain.
Journal of the American Medical Association.
320:508.
2018
|
|
| 2018
|
Moving Career Development Upstream: Evaluation of a Course for Internal Medicine Trainees Contemplating Career Pathways in Academic Medicine.
Southern Medical Journal.
111:471-475.
2018
|
|
| 2018
|
Hypophosphatemia in the setting of metabolic bone disease: case reports and diagnostic algorithm.
Therapeutic Advances in Musculoskeletal Disease.
10:151-156.
2018
|
|
| 2018
|
Improving drug adherence in osteoporosis: an update on more recent studies.
Therapeutic Advances in Musculoskeletal Disease.
10:141-149.
2018
|
|
| 2018
|
Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors.
Annals of the Rheumatic Diseases.
77:1012-1016.
2018
|
|
| 2018
|
A Performing Arts Intervention Improves Cognitive Dysfunction in 50 Hospitalized Older Adults.
Innovation in Aging.
2.
2018
|
|
| 2018
|
Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.
Lancet Diabetes and Endocrinology.
6:445-454.
2018
|
|
| 2018
|
Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: Phase II placebo-controlled study.
Arthritis Research and Therapy.
20.
2018
|
|
| 2018
|
Evaluation of a Multimodal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical Trial.
Journal of Bone and Mineral Research.
33:763-772.
2018
|
|
| 2018
|
Use of Scribes for Documentation Assistance in Rheumatology and Endocrinology Clinics: Impact on Clinic Workflow and Patient and Physician Satisfaction
2018
|
|
| 2018
|
Cardiovascular safety of febuxostat or allopurinol in patients with gout.
New England Journal of Medicine.
378:1200-1210.
2018
|
|
| 2018
|
Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: A population-based study.
Annals of the Rheumatic Diseases.
77:386-392.
2018
|
|
| 2018
|
Brief Report: Validation of a Definition of Flare in Patients With Established Gout.
Arthritis and Rheumatology.
70:462-467.
2018
|
|
| 2018
|
Hip fracture trends in the United States, 2002 to 2015.
Osteoporosis International.
29:717-722.
2018
|
|
| 2018
|
Development and Pilot Testing of Multimedia Patient Education Tools for Patients With Knee Osteoarthritis, Osteoporosis, and Rheumatoid Arthritis.
Arthritis Care and Research.
70:213-220.
2018
|
|
| 2018
|
Just the FRAX: Management of Glucocorticoid-Induced Osteoporosis.
Gastroenterology.
154:748-750.
2018
|
|
| 2018
|
Taking an Interdisciplinary Approach to Understanding and Improving Medication Adherence.
Journal of General Internal Medicine.
33:136-138.
2018
|
|
| 2018
|
Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.
New England Journal of Medicine.
378:195-196.
2018
|
|
| 2018
|
ACTIVExtend: 24 Months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis.
Journal of Clinical Endocrinology and Metabolism.
103:2949-2957.
2018
|
|
| 2018
|
Healthcare Providers' Recommendations for Physical Activity among US Arthritis Population: A Cross-Sectional Analysis by Race/Ethnicity..
Arthritis.
2018:2807035.
2018
|
|
| 2018
|
Routine use of quantitative disease activity measurements among us rheumatologists: Implications for treat-to-target management strategies in rheumatoid arthritis.
Journal of Rheumatology.
45:40-44.
2018
|
|
| 2017
|
Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study.
Arthritis and Rheumatology.
69:2386-2395.
2017
|
|
| 2017
|
Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: A 6 month phase 3 clinical trial and extension study.
Rheumatology.
56:2170-2178.
2017
|
|
| 2017
|
Screening questions for nonsteroidal anti-inflammatory drug risk knowledge.
Journal of Patient Safety.
13:217-222.
2017
|
|
| 2017
|
Self-perception of fracture risk: what can it tell us?.
Osteoporosis International.
28:3495-3500.
2017
|
|
| 2017
|
Validity, reliability, and responsiveness to change of the “Osteoporosis and You” knowledge scale.
Osteoporosis International.
28:3379-3388.
2017
|
|
| 2017
|
Response to the American College of Physicians Osteoporosis Guideline, 2017 Update.
Arthritis and Rheumatology.
69:2097-2101.
2017
|
|
| 2017
|
Serious Infections in Childhood-Onset Systemic Lupus Erythematosus: Using Administrative Claims Data to Investigate Disease Outcomes.
Arthritis Care and Research.
69:1617-1619.
2017
|
|
| 2017
|
The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the United States: supplementary presentation.
Osteoporosis International.
28:3283-3284.
2017
|
|
| 2017
|
Romosozumab or alendronate for fracture prevention in women with osteoporosis.
New England Journal of Medicine.
377:1417-1427.
2017
|
|
| 2017
|
Activating Patients With a Tailored Bone Density Test Results Letter and Educational Brochure: the PAADRN Randomized Controlled Trial.
Journal of Clinical Densitometry.
20:464-471.
2017
|
|
| 2017
|
Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis.
Arthritis Care and Research.
69:1526-1534.
2017
|
|
| 2017
|
The cost of a patient activation intervention for achieving successful outcomes: results from the PAADRN randomized controlled trial.
Osteoporosis International.
28:3061-3066.
2017
|
|
| 2017
|
The effects of a patient activation intervention on smoking and excessive drinking cessations: results from the PAADRN randomized controlled trial.
Osteoporosis International.
28:3055-3060.
2017
|
|
| 2017
|
Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United States.
Arthritis and Rheumatology.
69:1733-1740.
2017
|
|
| 2017
|
Discordant American College of Physicians and international rheumatology guidelines for gout management: Consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN).
Nature Reviews Rheumatology.
13:561-568.
2017
|
|
| 2017
|
Regional Differences in Incident Prefrailty and Frailty.
Journal of Women's Health.
26:992-998.
2017
|
|
| 2017
|
Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study.
Osteoporosis International.
28:2495-2503.
2017
|
|
| 2017
|
Erratum to: Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study (Osteoporosis International, (2017), 28, 8, (2495-2503), 10.1007/s00198-017-4073-5).
Osteoporosis International.
28:2505.
2017
|
|
| 2017
|
Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases.
Journal of Rheumatology.
44:1083-1087.
2017
|
|
| 2017
|
Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy
2017
|
|
| 2017
|
Management of gout.
ACP journal club.
166:855.
2017
|
|
| 2017
|
Reply.
Arthritis and Rheumatology.
69:1122.
2017
|
|
| 2017
|
The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USA.
Osteoporosis International.
28:1225-1232.
2017
|
|
| 2017
|
Treat-To-Target (T2T) recommendations for gout.
Annals of the Rheumatic Diseases.
76:632-638.
2017
|
|
| 2017
|
Sex differences in gout characteristics: Tailoring care for women and men.
BMC Musculoskeletal Disorders.
18.
2017
|
|
| 2017
|
Addressing the Crisis in the Treatment of Osteoporosis: A Path Forward.
Journal of Bone and Mineral Research.
32:424-430.
2017
|
|
| 2017
|
Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis.
Annals of the Rheumatic Diseases.
76:543-546.
2017
|
|
| 2017
|
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
Annals of the Rheumatic Diseases.
76:960-977.
2017
|
|
| 2017
|
Evaluation of a "Just-in-Time" Nurse Consultation on Bone Health: A Pilot Randomized Controlled Trial.
The Permanente Journal.
21.
2017
|
|
| 2017
|
Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study).
Arthritis and Rheumatology.
69:203-212.
2017
|
|
| 2017
|
Racial Differences and Disparities in Osteoporosis-related Bone Health: Results from the PAADRN Randomized Controlled Trial.
Medical Care.
55:561-568.
2017
|
|
| 2017
|
Understanding Preferences for Osteoporosis Information to Develop an Osteoporosis Patient Education Brochure.
The Permanente Journal.
21.
2017
|
|
| 2016
|
A multi-modal intervention for Activating Patients at Risk for Osteoporosis (APROPOS): Rationale, design, and uptake of online study intervention material.
Contemporary Clinical Trials Communications.
4:14-24.
2016
|
|
| 2016
|
Understanding practice-based research participation: The differing motivations of engaged vs. non-engaged clinicians in pragmatic clinical trials.
Contemporary Clinical Trials Communications.
4:136-140.
2016
|
|
| 2016
|
Patient-activation and guideline-concordant pharmacological treatment after bone density testing: the PAADRN randomized controlled trial.
Osteoporosis International.
27:3513-3524.
2016
|
|
| 2016
|
The National Osteoporosis Foundation’s methods and processes for developing position statements.
Archives of Osteoporosis.
11.
2016
|
|
| 2016
|
Cost-effectiveness of Low-dose Submicron Diclofenac Compared With Generic Diclofenac
2016
|
|
| 2016
|
Evaluating the effectiveness of a patient storytelling DVD intervention to encourage physician-patient communication about nonsteroidal anti-inflammatory drug (NSAID) use.
Patient Education and Counseling.
99:1837-1844.
2016
|
|
| 2016
|
Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis.
Osteoporosis International.
27:3239-3249.
2016
|
|
| 2016
|
Combining Computed Tomography-Based Bone Density Assessment with FRAX Screening in Men with Prostate Cancer.
Journal of Clinical Densitometry.
19:430-435.
2016
|
|
| 2016
|
Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis.
Annals of the Rheumatic Diseases.
75:1813-1818.
2016
|
|
| 2016
|
Reply.
Arthritis and Rheumatology.
68:2564.
2016
|
|
| 2016
|
Socio-demographic differences in risk information seeking sources for non-steroidal anti-inflammatory drugs (NSAIDS).
International Journal of Medical Informatics.
94:222-227.
2016
|
|
| 2016
|
Patient's experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis.
BMC Musculoskeletal Disorders.
17.
2016
|
|
| 2016
|
The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis.
Arthritis Research and Therapy.
18.
2016
|
|
| 2016
|
Analysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patients
2016
|
|
| 2016
|
Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study.
Contemporary Clinical Trials.
50:106-115.
2016
|
|
| 2016
|
Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination.
Arthritis and Rheumatology.
68:2328-2337.
2016
|
|
| 2016
|
The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale.
Contemporary Clinical Trials.
50:238-244.
2016
|
|
| 2016
|
Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy–Induced Osteoporosis Treated With Alendronate or Teriparatide.
Arthritis and Rheumatology.
68:2122-2128.
2016
|
|
| 2016
|
Effects of a DXA result letter on satisfaction, quality of life, and osteoporosis knowledge: A randomized controlled trial.
BMC Musculoskeletal Disorders.
17.
2016
|
|
| 2016
|
A pragmatic randomized trial comparing tablet computer informed consent to traditional paper-based methods for an osteoporosis study.
Contemporary Clinical Trials Communications.
3:32-38.
2016
|
|
| 2016
|
Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment.
Arthritis and Rheumatology.
68:2035-2043.
2016
|
|
| 2016
|
Increase in Fracture Risk Following Unintentional Weight Loss in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women.
Journal of Bone and Mineral Research.
31:1466-1472.
2016
|
|
| 2016
|
Reply.
Arthritis and Rheumatology.
68:1316-1318.
2016
|
|
| 2016
|
Reply.
Arthritis Care and Research.
68:725-726.
2016
|
|
| 2016
|
Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).
Aging Clinical and Experimental Research.
28.
2016
|
|
| 2016
|
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
Arthritis and Rheumatology.
68:1-26.
2016
|
|
| 2016
|
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
Arthritis Care and Research.
68:1-26.
2016
|
|
| 2016
|
Comparative Risk of Hospitalized Infection Associated with Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
Arthritis and Rheumatology.
68:56-66.
2016
|
|
| 2016
|
Glucocorticoid-induced Osteoporosis.
Rheumatic Disease Clinics of North America.
42:177-189.
2016
|
|
| 2015
|
The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population.
British Journal of Clinical Pharmacology.
80:1447-1457.
2015
|
|
| 2015
|
2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative.
Arthritis and Rheumatology.
67:2557-2568.
2015
|
|
| 2015
|
2015 Gout classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative.
Annals of the Rheumatic Diseases.
74:1789-1798.
2015
|
|
| 2015
|
What is the relationship between morning symptoms and measures of disease activity in patients with rheumatoid arthritis?.
Arthritis Care and Research.
67:1202-1209.
2015
|
|
| 2015
|
Bisphosphonates and glucocorticoid-induced osteoporosis: cons.
Endocrine.
49:628-634.
2015
|
|
| 2015
|
An internet-based controlled trial aimed to improve osteoporosis prevention among chronic glucocorticoid users.
Journal of Rheumatology.
42:1478-1483.
2015
|
|
| 2015
|
The validity of claims-based algorithms to identify serious hypersensitivity reactions and osteonecrosis of the jaw.
PLoS One.
10.
2015
|
|
| 2015
|
Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology.
Annals of the Rheumatic Diseases.
74:963-969.
2015
|
|
| 2015
|
Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.
Annals of the Rheumatic Diseases.
74:1065-1071.
2015
|
|
| 2015
|
Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.
Arthritis and Rheumatology.
67:1456-1464.
2015
|
|
| 2015
|
Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.
Arthritis Care and Research.
67:624-632.
2015
|
|
| 2015
|
Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.
Arthritis Care and Research.
67:731-736.
2015
|
|
| 2015
|
Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.
Journal of Rheumatology.
42:504-512.
2015
|
|
| 2015
|
Balancing the benefits and risks of low-dose glucocorticoid in rheumatoid arthritis.
Acta Reumatologica Portuguesa.
2015:10-22.
2015
|
|
| 2015
|
Balancing the benefits and risks of low-dose glucocorticoid in rheumatoid arthritis..
Acta Reumatologica Portuguesa.
40:10-22.
2015
|
|
| 2015
|
Evaluating and mitigating fracture risk in established rheumatoid arthritis.
Best Practice and Research: Clinical Rheumatology.
29:614-627.
2015
|
|
| 2015
|
Fractures and mortality in relation to different osteoporosis treatments.
Clinical and Experimental Rheumatology.
33:302-309.
2015
|
|
| 2015
|
International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study.
Osteoporosis International.
26:419-420.
2015
|
|
| 2014
|
The safety of low-dose glucocorticoids in rheumatic diseases: Results from observational studies.
Neuroimmunomodulation.
22:72-82.
2014
|
|
| 2014
|
Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: Results of the SAfety assessment of biologic ThERapy (SABER) study.
Annals of the Rheumatic Diseases.
73:1942-1948.
2014
|
|
| 2014
|
The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine.
Journal of Bone and Mineral Research.
29:2520-2526.
2014
|
|
| 2014
|
Use of Oral and Subcutaneous Methotrexate in Rheumatoid Arthritis Patients in the United States.
Arthritis Care and Research.
66:1604-1611.
2014
|
|
| 2014
|
Bisphosphonates and hip and nontraumatic subtrochanteric femoral fractures in the veterans health administration
2014
|
|
| 2014
|
Developing a bone mineral density test result letter to send to patients: A mixed-methods study.
Patient Preference and Adherence.
8:827-841.
2014
|
|
| 2014
|
Relationship between diclofenac dose and risk of gastrointestinal and cardiovascular events: Meta-regression based on two systematic literature reviews
2014
|
|
| 2014
|
The clinical diagnosis of osteoporosis: A position statement from the National Bone Health Alliance Working Group.
Osteoporosis International.
25:1439-1443.
2014
|
|
| 2014
|
Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries.
BMC Musculoskeletal Disorders.
15.
2014
|
|
| 2014
|
Death, debility, and destitution following hip fracture
2014
|
|
| 2014
|
Obesity, health-care utilization, and health-related quality of life after fracture in postmenopausal women: Global longitudinal study of osteoporosis in women (GLOW).
Calcified Tissue International.
94:223-231.
2014
|
|
| 2014
|
Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: The global longitudinal study of osteoporosis in women (GLOW).
Journal of Bone and Mineral Research.
29:487-493.
2014
|
|
| 2014
|
Use of health plan combined with registry data to predict clinical trial recruitment.
Clinical Trials.
11:96-101.
2014
|
|
| 2014
|
A group-randomized trial of shared decision making for non-steroidal anti-inflammatory drug risk awareness: Primary Results and lessons learned.
Journal of Evaluation in Clinical Practice.
20:638-648.
2014
|
|
| 2014
|
Bone safety of low-dose glucocorticoids in rheumatic diseases.
Annals of the New York Academy of Sciences.
1318:55-64.
2014
|
|
| 2014
|
Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study.
Osteoporosis International.
25:85-95.
2014
|
|
| 2014
|
Effect of self-referral on bone mineral density testing and osteoporosis treatment.
Medical Care.
52:743-750.
2014
|
|
| 2014
|
Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW).
Journal of Clinical Endocrinology and Metabolism.
99:817-826.
2014
|
|
| 2014
|
Fracture mortality: Associations with epidemiology and osteoporosis treatment.
Nature Reviews Endocrinology.
10:592-602.
2014
|
|
| 2014
|
Improving bone mineral density reporting to patients with an illustration of personal fracture risk.
BMC Medical Informatics and Decision Making.
14.
2014
|
|
| 2014
|
OMERACT endorsement of measures of outcome for studies of acute gout.
Journal of Rheumatology.
41:569-573.
2014
|
|
| 2014
|
RE: Drug risk assessment and data reuse.
Pharmacoepidemiology and Drug Safety.
23:109-110.
2014
|
|
| 2014
|
Risk factors for treatment failure with antiosteoporosis medication: The global longitudinal study of osteoporosis in women (GLOW).
Journal of Bone and Mineral Research.
29:260-267.
2014
|
|
| 2014
|
Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.
Arthritis Care and Research.
66:990-997.
2014
|
|
| 2014
|
Trends in the utilization and outcomes of medicare patients hospitalized for hip fracture, 2000-2008.
Journal of Aging and Health.
26:360-379.
2014
|
|
| 2014
|
Use of pharmacologic agents for the primary prevention of osteoporosis among older women with low bone mass.
Osteoporosis International.
25:317-324.
2014
|
|
| 2013
|
When, where and how osteoporosis-associated fractures occur: An analysis from the global longitudinal study of osteoporosis in women (GLOW).
PLoS One.
8.
2013
|
|
| 2013
|
Glucocorticoid-related bone changes from endogenous or exogenous glucocorticoids.
Current Opinion in Endocrinology, Diabetes and Obesity.
20:510-516.
2013
|
|
| 2013
|
Prevention and treatment of bone changes associated with exposure to glucocorticoids.
Current Osteoporosis Reports.
11:341-347.
2013
|
|
| 2013
|
Tumor necrosis factor, tuberculosis, testing, and treatment: Teeing up the questions.
Arthritis Care and Research.
65:1719-1721.
2013
|
|
| 2013
|
Tumor necrosis factor, tuberculosis, testing, and treatment: teeing up the questions..
Arthritis Care and Research.
65:1719-1721.
2013
|
|
| 2013
|
Challenges in defining quality of care for glucocorticoid-induced osteoporosis: Defending good against perfect.
Journal of Rheumatology.
40:1640-1642.
2013
|
|
| 2013
|
Multimodal intervention to improve osteoporosis care in home health settings: Results from a cluster randomized trial.
Osteoporosis International.
24:2555-2560.
2013
|
|
| 2013
|
Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs.
Pharmacoepidemiology and Drug Safety.
22:1036-1045.
2013
|
|
| 2013
|
Seizure occurrence following nonoptimal anticonvulsant medication management during the transition into the hospital.
Journal of Child Neurology.
28:1250-1258.
2013
|
|
| 2013
|
Serum urate association with hypertension in young adults: Analysis from the Coronary Artery Risk Development in Young Adults cohort.
Annals of the Rheumatic Diseases.
72:1321-1327.
2013
|
|
| 2013
|
Serum urate levels and consumption of common beverages and alcohol among chinese in Singapore.
Arthritis Care and Research.
65:1432-1440.
2013
|
|
| 2013
|
Study design considerations for a large simple trial of bisphosphonates.
Current Opinion in Rheumatology.
25:517-523.
2013
|
|
| 2013
|
Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-sentinel Program.
JAMA Internal Medicine.
173:817-819.
2013
|
|
| 2013
|
Brief report: Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis.
Arthritis and Rheumatism.
65:1384-1389.
2013
|
|
| 2013
|
Reply.
Arthritis Care and Research.
65:832-833.
2013
|
|
| 2013
|
A close examination of healthcare expenditures related to fractures.
Journal of Bone and Mineral Research.
28:816-820.
2013
|
|
| 2013
|
Association between anti-TNF-α therapy and interstitial lung disease.
Pharmacoepidemiology and Drug Safety.
22:394-402.
2013
|
|
| 2013
|
Association between osteoporosis treatment change and adherence, incident fracture, and total healthcare costs in a Medicare Advantage Prescription Drug plan.
Osteoporosis International.
24:1195-1206.
2013
|
|
| 2013
|
Gout-related health care utilization in US emergency departments, 2006 through 2008.
Arthritis Care and Research.
65:571-577.
2013
|
|
| 2013
|
Osteoporosis Diagnosis and Medical Treatment.
Orthopedic Clinics of North America.
44:125-135.
2013
|
|
| 2013
|
Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.
Journal of the American Medical Association.
309:887-895.
2013
|
|
| 2013
|
Anticonvulsant medication errors in children with epilepsy during the home-to-hospital transition.
Journal of Child Neurology.
28:314-320.
2013
|
|
| 2013
|
Low-dose prednisone chronotherapy for rheumatoid arthritis: A randomised clinical trial (CAPRA-2).
Annals of the Rheumatic Diseases.
72:204-210.
2013
|
|
| 2013
|
Physicians' explanations for apparent gaps in the quality of rheumatology care: Results from the US Medicare Physician Quality Reporting System.
Arthritis Care and Research.
65:235-243.
2013
|
|
| 2013
|
Cardiovascular risk in rheumatoid arthritis: Comparing tnf-α blockade with nonbiologic DMARDs.
American Journal of Medicine.
126:730.e9-730.e17.
2013
|
|
| 2013
|
Choosing wisely: The American College of Rheumatology's top 5 list of things physicians and patients should question.
Arthritis Care and Research.
65:329-339.
2013
|
|
| 2013
|
Generic alendronate use among medicare beneficiaries: Are part d data complete?.
Pharmacoepidemiology and Drug Safety.
22:55-63.
2013
|
|
| 2013
|
Initiation of anti-TNF therapy and the risk of optic neuritis: From the safety assessment of biologic ThERapy (SABER) study.
American Journal of Ophthalmology.
155:183-189.e1.
2013
|
|
| 2013
|
Non-hip, non-spine fractures drive healthcare utilization following a fracture: The Global Longitudinal Study of Osteoporosis in Women (GLOW).
Osteoporosis International.
24:59-67.
2013
|
|
| 2013
|
Osteopenia: Debates and dilemmas.
Current Rheumatology Reports.
15.
2013
|
|
| 2013
|
Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug members in a national health plan.
Journal of Evaluation in Clinical Practice.
19:50-59.
2013
|
|
| 2013
|
The PAADRN Study: A design for a randomized controlled practical clinical trial to improve bone health.
Contemporary Clinical Trials.
34:90-100.
2013
|
|
| 2013
|
Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program.
Arthritis Care and Research.
65:1743-1751.
2013
|
|
| 2013
|
Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases.
Arthritis and Rheumatism.
65:48-58.
2013
|
|
| 2013
|
Using tablet computers compared to interactive voice response to improve subject recruitment in osteoporosis pragmatic clinical trials: Feasibility, satisfaction, and sample size.
Patient Preference and Adherence.
7:517-523.
2013
|
|
| 2012
|
A randomized trial of a mailed intervention and self-scheduling to improve osteoporosis screening in postmenopausal women.
Journal of Bone and Mineral Research.
27:2603-2610.
2012
|
|
| 2012
|
Association between anti-TNF-α therapy and all-cause mortality.
Pharmacoepidemiology and Drug Safety.
21:1311-1320.
2012
|
|
| 2012
|
Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: The Global Longitudinal study of Osteoporosis in Women (GLOW).
Osteoporosis International.
23:2863-2871.
2012
|
|
| 2012
|
Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational data.
Arthritis Care and Research.
64:1855-1863.
2012
|
|
| 2012
|
Preliminary Competencies for Comparative Effectiveness Research.
Clinical and Translational Science.
5:476-479.
2012
|
|
| 2012
|
Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States.
Contemporary Clinical Trials.
33:1211-1216.
2012
|
|
| 2012
|
Recent trends in hip fracture rates by race/ethnicity among older US adults.
Journal of Bone and Mineral Research.
27:2325-2332.
2012
|
|
| 2012
|
Short-term and long-term safety of glucocorticoids in rheumatoid arthritis
2012
|
|
| 2012
|
Reply.
Arthritis Care and Research.
64:1623-1624.
2012
|
|
| 2012
|
Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
Arthritis Care and Research.
64:1462-1470.
2012
|
|
| 2012
|
Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high-versus lower-risk rheumatoid arthritis patients.
Arthritis Care and Research.
64:1480-1489.
2012
|
|
| 2012
|
Acknowledgments for "best practices in systems-based interventions to reduce the burden of fractures" (Osteoporosis International Volume 22, Supplement 3, August 2011).
Osteoporosis International.
23:2393-2394.
2012
|
|
| 2012
|
Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment.
Arthritis and Rheumatism.
64:2773-2780.
2012
|
|
| 2012
|
Regional and age-related variations in the proportions of hip fractures and major fractures among postmenopausal women: The Global Longitudinal Study of Osteoporosis in Women.
Osteoporosis International.
23:2179-2188.
2012
|
|
| 2012
|
The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
Osteoporosis International.
23:2141-2150.
2012
|
|
| 2012
|
Association between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection among Older Patients with Selected Immune-Mediated Diseases.
Journal of the American Medical Association.
308:43-49.
2012
|
|
| 2012
|
Adherence with intravenous zoledronate and intravenous ibandronate in the United States medicare population.
Arthritis Care and Research.
64:1054-1060.
2012
|
|
| 2012
|
Effect of co-morbidities on fracture risk: Findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).
Bone.
50:1288-1293.
2012
|
|
| 2012
|
From fracture risk prediction to evaluating fracture patterns: Recent advances in the epidemiology of osteoporosis.
Current Rheumatology Reports.
14:205-211.
2012
|
|
| 2012
|
Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study.
Annals of the Rheumatic Diseases.
71:924-928.
2012
|
|
| 2012
|
Rheumatoid arthritis disease activity measures: American college of rheumatology recommendations for use in clinical practice.
Arthritis Care and Research.
64:640-647.
2012
|
|
| 2012
|
Central DXA utilization shifts from office-based to hospital-based settings among medicare beneficiaries in the wake of reimbursement changes.
Journal of Bone and Mineral Research.
27:858-864.
2012
|
|
| 2012
|
Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases.
Arthritis Care and Research.
64:612-615.
2012
|
|
| 2012
|
Corrigendum to "Bisphosphonates and glucocorticoid osteoporosis in men: Results of a randomized controlled trial comparing zoledronic acid with risedronate" [Bone 50 (2012) 289-295].
Bone.
50:811.
2012
|
|
| 2012
|
Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Osteoporosis International.
23:1083-1090.
2012
|
|
| 2012
|
Previous fractures at multiple sites increase the risk for subsequent fractures: The global longitudinal study of osteoporosis in women.
Journal of Bone and Mineral Research.
27:645-653.
2012
|
|
| 2012
|
Drug treatment of hyperuricemia to prevent cardiovascular outcomes: Are we there yet?.
American Journal of Cardiovascular Drugs.
12:1-6.
2012
|
|
| 2012
|
Association between being African-American, serum urate levels and the risk of developing hyperuricemia: Findings from the Coronary Artery Risk Development in Young Adults cohort.
Arthritis Research and Therapy.
14.
2012
|
|
| 2012
|
2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.
Arthritis Care and Research.
64:625-639.
2012
|
|
| 2012
|
Bisphosphonates and glucocorticoid osteoporosis in men: Results of a randomized controlled trial comparing zoledronic acid with risedronate.
Bone.
50:289-295.
2012
|
|
| 2012
|
Developing a provisional definition of flare in patients with established gout.
Arthritis and Rheumatism.
64:1508-1517.
2012
|
|
| 2012
|
Evaluating comorbidity scores based on health service expenditures.
Health care financing review.
2.
2012
|
|
| 2012
|
Improving osteoporosis care in high-risk home health patients through a high-intensity intervention.
Contemporary Clinical Trials.
33:206-212.
2012
|
|
| 2012
|
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment..
Arthritis and Rheumatism.
64:1263-1271.
2012
|
|
| 2012
|
Reply.
Arthritis Care and Research.
64:157-158.
2012
|
|
| 2012
|
Validation of Diagnostic Codes for Subtrochanteric, Diaphyseal, and Atypical Femoral Fractures Using Administrative Claims Data.
Journal of Clinical Densitometry.
15:92-102.
2012
|
|
| 2011
|
Initiation of tumor necrosis factor-αantagonists and the risk of hospitalization for infection in patients with autoimmune diseases.
Journal of the American Medical Association.
306:2331-2339.
2011
|
|
| 2011
|
The safety of low-dose glucocorticoids in rheumatic diseases.
Clinical and Experimental Rheumatology.
29.
2011
|
|
| 2011
|
Predicting fractures in an international cohort using risk factor algorithms without BMD.
Journal of Bone and Mineral Research.
26:2770-2777.
2011
|
|
| 2011
|
Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems.
Pharmacoepidemiology and Drug Safety.
20:1199-1209.
2011
|
|
| 2011
|
Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis.
Arthritis Research and Therapy.
13.
2011
|
|
| 2011
|
Is two better than one? Combining antiresorptive and anabolic osteoporosis medications.
Current Osteoporosis Reports.
9:109-111.
2011
|
|
| 2011
|
Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW).
Bone.
49:493-498.
2011
|
|
| 2011
|
Reply.
Arthritis Care and Research.
63:1355.
2011
|
|
| 2011
|
Long-term safety concerns of antiresorptive therapy.
Rheumatic Disease Clinics of North America.
37:387-400.
2011
|
|
| 2011
|
Systems-based approaches to osteoporosis and fracture care: Policy and research recommendations from the workgroups.
Osteoporosis International.
22.
2011
|
|
| 2011
|
The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents.
Annals of the Rheumatic Diseases.
70:1401-1406.
2011
|
|
| 2011
|
Bringing it all together: A novel approach to the development of response criteria for chronic gout clinical trials.
Journal of Rheumatology.
38:1467-1470.
2011
|
|
| 2011
|
Official Positions for FRAX® Clinical Regarding Glucocorticoids: The impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture. From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®M.
Journal of Clinical Densitometry.
14:212-219.
2011
|
|
| 2011
|
Communicating non-steroidal anti-inflammatory drug risks: Verbal counseling, written medicine information, and patients' risk awareness.
Patient Education and Counseling.
83:391-397.
2011
|
|
| 2011
|
Potential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapies.
Current Rheumatology Reports.
13:273-282.
2011
|
|
| 2011
|
Response to Letter to Editor on validation study identifying bacterial infections in rheumatoid arthritis patients.
Journal of Clinical Epidemiology.
64:573.
2011
|
|
| 2011
|
Erratum: Clinical and demographic factors associated with fractures among older Americans (Osteoporosis International DOI: 10.1007/s00198-010-1300-8).
Osteoporosis International.
22:1275-1276.
2011
|
|
| 2011
|
Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?.
Arthritis and Rheumatism.
63:325-328.
2011
|
|
| 2011
|
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features..
Arthritis Care and Research.
63:465-482.
2011
|
|
| 2011
|
An observational study of glucocorticoid-induced osteoporosis prophylaxis in a national cohort of male veterans with rheumatoid arthritis.
Osteoporosis International.
22:305-315.
2011
|
|
| 2011
|
Clinical and demographic factors associated with fractures among older Americans.
Osteoporosis International.
22:1263-1274.
2011
|
|
| 2011
|
Defining quality of care in rheumatology: The American College of rheumatology white paper on quality measurement.
Arthritis Care and Research.
63:2-9.
2011
|
|
| 2011
|
Failure to perceive increased risk of fracture in women 55 years and older: The Global Longitudinal Study of Osteoporosis in Women (GLOW).
Osteoporosis International.
22:27-35.
2011
|
|
| 2011
|
Obesity is not protective against fracture in postmenopausal women: Glow.
American Journal of Medicine.
124:1043-1050.
2011
|
|
| 2011
|
Which fractures are most attributable to osteoporosis?.
Journal of Clinical Epidemiology.
64:46-53.
2011
|
|
| 2010
|
Serum urate and its relationship with alcoholic beverage intake in men and women: Findings from the Coronary Artery Risk Development in Young Adults (CARDIA) cohort.
Annals of the Rheumatic Diseases.
69:1965-1970.
2010
|
|
| 2010
|
Osteoporosis care in the United States after declines in reimbursements for DXA.
Journal of Clinical Densitometry.
13:352-360.
2010
|
|
| 2010
|
Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis.
Osteoporosis International.
21:1573-1584.
2010
|
|
| 2010
|
Health services utilization after fractures: Evidence from Medicare
2010
|
|
| 2010
|
Medication assistance programs: Do all in need benefit equally?
2010
|
|
| 2010
|
From bone biology to clinical outcome: State of the art and future perspectives.
Annals of the Rheumatic Diseases.
69:1415-1419.
2010
|
|
| 2010
|
The delivery of evidence-based preventive care for older Americans with arthritis.
Arthritis Research and Therapy.
12.
2010
|
|
| 2010
|
Current Opinion in Rheumatology: Editorial introductions.
Current Opinion in Rheumatology.
22.
2010
|
|
| 2010
|
Identifying types of nursing facility stays using medicare claims data: An algorithm and validation
2010
|
|
| 2010
|
Patient and rheumatologist perspectives on glucocorticoids: An exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.
Annals of the Rheumatic Diseases.
69:1015-1021.
2010
|
|
| 2010
|
Reply.
Arthritis and Rheumatism.
62:1837-1838.
2010
|
|
| 2010
|
Using single-item health literacy screening questions to identify patients who read written nonsteroidal anti-inflammatory medicine information provided at pharmacies
2010
|
|
| 2010
|
Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Bone.
46:929-934.
2010
|
|
| 2010
|
(Journal of Rheumatology (2009) 36, (2114) DOI:10.3899/jrheum.090591).
Journal of Rheumatology.
37:681.
2010
|
|
| 2010
|
The role of health literacy and written medicine information in nonsteroidal antiinflammatory drug risk awareness.
Annals of Pharmacotherapy.
44:274-284.
2010
|
|
| 2010
|
American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis..
Arthritis Care and Research.
62:1515-1526.
2010
|
|
| 2010
|
Health literacy and happiness: A community-based study
2010
|
|
| 2010
|
Impact of prevalent fractures on quality of life: Baseline results from the global longitudinal study of osteoporosis in women.
Mayo Clinic Proceedings.
85:806-813.
2010
|
|
| 2010
|
Is withholding osteoporosis medication after fracture sometimes rational? A Comparison of the risk for second fracture versus death
2010
|
|
| 2009
|
Febuxostat: The evidence for its use in the treatment of hyperuricemia and gout.
Core Evidence.
4:25-36.
2009
|
|
| 2009
|
Health care expenditures associated with skeletal fractures among medicare beneficiaries, 1999-2005.
Journal of Bone and Mineral Research.
24:2050-2055.
2009
|
|
| 2009
|
"pathologic" fractures: Should these be included in epidemiologic studies of osteoporotic fractures?.
Osteoporosis International.
20:1969-1972.
2009
|
|
| 2009
|
Do physicians within the same practice setting manage osteoporosis patients similarly? Implications for implementation research.
Osteoporosis International.
20:1921-1927.
2009
|
|
| 2009
|
Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial.
Arthritis and Rheumatism.
60:3346-3355.
2009
|
|
| 2009
|
Progress in osteoporosis and fracture prevention: Focus on postmenopausal women.
Arthritis Research and Therapy.
11.
2009
|
|
| 2009
|
Quality health care gaps in osteoporosis: How can patients, providers, and the health system do a better job?.
Current Osteoporosis Reports.
7:27-34.
2009
|
|
| 2009
|
Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis.
Journal of Bone and Mineral Research.
24:1643-1646.
2009
|
|
| 2009
|
Estimated prevalence and patterns of presumed osteoporosis among older Americans based on Medicare data.
Osteoporosis International.
20:1507-1515.
2009
|
|
| 2009
|
The geographic availability and associated utilization of dual-energy X-ray absorptiometry (DXA) testing among older persons in the United States.
Osteoporosis International.
20:1553-1561.
2009
|
|
| 2009
|
Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?.
Arthritis Research and Therapy.
11.
2009
|
|
| 2009
|
Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: A 12-month randomized, placebo-controlled clinical trial.
Journal of Rheumatology.
36:1705-1714.
2009
|
|
| 2009
|
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (health outcomes and reduced incidence with zoledronic acid once yearly trial): A multicentre, double-blind, double-dummy, randomized controlled trial.
Obstetrical and Gynecological Survey.
64:521-523.
2009
|
|
| 2009
|
Editorial introductions.
Current Opinion in Rheumatology.
21.
2009
|
|
| 2009
|
The Global Longitudinal Study of Osteoporosis in Women (GLOW): Rationale and study design.
Osteoporosis International.
20:1107-1116.
2009
|
|
| 2009
|
RisedronatE and ALendronate intervention over three years (REALITY): Minimal differences in fracture risk reduction.
Osteoporosis International.
20:973-978.
2009
|
|
| 2009
|
Health and happiness among older adults: A community-based study.
Journal of Health Psychology.
14:503-512.
2009
|
|
| 2009
|
Vertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: A population-based cohort study.
Osteoporosis International.
20:819-826.
2009
|
|
| 2009
|
Toward a Valid Definition of Gout Flare: Results of Consensus Exercises Using Delphi Methodology and Cognitive Mapping.
Arthritis and Rheumatism.
61:535-543.
2009
|
|
| 2009
|
Management of osteoporosis among home health and long-term care patients with a prior fracture.
Southern Medical Journal.
102:397-404.
2009
|
|
| 2009
|
Improving the prediction of medication compliance: The example of bisphosphonates for osteoporosis.
Medical Care.
47:334-341.
2009
|
|
| 2009
|
To the Editors.
Arthritis and Rheumatism.
61:285-286.
2009
|
|
| 2009
|
Reply.
Arthritis and Rheumatism.
61:142.
2009
|
|
| 2009
|
Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients.
Journal of Clinical Epidemiology.
62.
2009
|
|
| 2009
|
Are glucocorticoids equivalent to NSAIDs for the treatment of gout flares?.
Nature Reviews Rheumatology.
5:12-13.
2009
|
|
| 2009
|
Bridging the osteoporosis quality chasm.
Journal of Bone and Mineral Research.
24:3-7.
2009
|
|
| 2009
|
Glucocorticoids and the risk of osteoporosis.
Expert Opinion on Drug Safety.
8:33-47.
2009
|
|
| 2009
|
How to ascertain drug safety in the context of benefit. Controversies and concerns.
Journal of Rheumatology.
36:2114-2121.
2009
|
|
| 2009
|
Identification and validation of vertebral compression fractures using administrative claims data.
Medical Care.
47:69-72.
2009
|
|
| 2009
|
Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and Europe.
American Journal of Medicine.
122:S3.
2009
|
|
| 2009
|
Patient-reported communications with pharmacy staff at community pharmacies: The Alabama NSAID Patient Safety Study, 2005-2007
2009
|
|
| 2009
|
Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender.
Journal of General Internal Medicine.
24:956-962.
2009
|
|
| 2009
|
Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates.
Journal of Clinical Endocrinology and Metabolism.
94:1097-1103.
2009
|
|
| 2009
|
Strategies for treating rheumatoid arthritis: New guidelines from the ACR.
International Journal of Clinical Rheumatology.
4:3-5.
2009
|
|
| 2009
|
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial
2009
|
|
| 2008
|
Effect of racial differences on ability to afford prescription medications.
American Journal of Health-System Pharmacy.
65:2137-2143.
2008
|
|
| 2008
|
Management of Hyperuricemia and Gout in CKD.
American Journal of Kidney Diseases.
52:994-1009.
2008
|
|
| 2008
|
Risk of hip fracture after bisphosphonate discontinuation: Implications for a drug holiday.
Osteoporosis International.
19:1613-1620.
2008
|
|
| 2008
|
The effect of thiazolidinediones on BMD and osteoporosis (Nature Clinical Practice Endocrinology and Metabolism (2008) 4, (507-513) DOI:10.1038/ ncpendmet0920).
Nature Reviews Endocrinology.
4:643.
2008
|
|
| 2008
|
Bisphosphonates for osteoarthritis prevention: "Holy Grail" or not?.
Annals of the Rheumatic Diseases.
67:1358-1359.
2008
|
|
| 2008
|
Regional Variation in the Denial of Reimbursement for Bone Mineral Density Testing Among US Medicare Beneficiaries.
Journal of Clinical Densitometry.
11:568-574.
2008
|
|
| 2008
|
Adaptation of bayesian data mining algorithms to longitudinal claims data: Coxib safety as an example.
Medical Care.
46:969-975.
2008
|
|
| 2008
|
Benefit of adherence with bisphosphonates depends on age and fracture type: Results from an analysis of 101,038 new bisphosphonate users.
Journal of Bone and Mineral Research.
23:1435-1441.
2008
|
|
| 2008
|
Mortality and osteoporotic fractures: Is the link causal, and is it modifiable?.
Clinical and Experimental Rheumatology.
26.
2008
|
|
| 2008
|
The effect of thiazolidinediones on BMD and osteoporosis.
Nature Reviews Endocrinology.
4:507-513.
2008
|
|
| 2008
|
Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: An American College of Rheumatology white paper.
Arthritis and Rheumatism.
59:1058-1073.
2008
|
|
| 2008
|
Longitudinal trends in use of bone mass measurement among older Americans, 1999-2005.
Journal of Bone and Mineral Research.
23:1061-1067.
2008
|
|
| 2008
|
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.
Arthritis and Rheumatism.
59:762-784.
2008
|
|
| 2008
|
Association of infections and tuberculosis with antitumor necrosis factor alpha therapy.
Current Opinion in Rheumatology.
20:320-326.
2008
|
|
| 2008
|
Biologics and heart failure in rheumatoid arthritis: Are we any wiser?.
Current Opinion in Rheumatology.
20:327-333.
2008
|
|
| 2008
|
Drug Insight: Choosing a drug treatment strategy for women with osteoporosis - An evidence-based clinical perspective.
Nature Reviews Rheumatology.
4:240-248.
2008
|
|
| 2008
|
Improving quality of care in osteoporosis: Opportunities and challenges.
Current Rheumatology Reports.
10:123-130.
2008
|
|
| 2008
|
Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Obstetrical and Gynecological Survey.
63:232-233.
2008
|
|
| 2008
|
The use of zoledronic acid for osteoporosis..
Current Rheumatology Reports.
10:89-91.
2008
|
|
| 2008
|
Therapeutic advances in calcium and vitamin D for osteoporosis..
Current Rheumatology Reports.
10:90-91.
2008
|
|
| 2008
|
The authors reply.
New England Journal of Medicine.
358:1303-1304.
2008
|
|
| 2008
|
The epidemiology of glucocorticoid-associated adverse events.
Current Opinion in Rheumatology.
20:131-137.
2008
|
|
| 2008
|
Association of health-related quality of life with dual use of prescription and over-the-counter nonsteroidal antiinflammatory drugs.
Arthritis and Rheumatism.
59:227-233.
2008
|
|
| 2008
|
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.
Journal of Clinical Endocrinology and Metabolism.
93:3785-3793.
2008
|
|
| 2008
|
Mortality and osteoporotic fractures: is the link causal, and is it modifiable?.
Clinical and Experimental Rheumatology.
26:S125-S137.
2008
|
|
| 2008
|
Serum urate, menopause, and postmenopausal hormone use: from eminence to evidence-based medicine..
Arthritis Research and Therapy.
10:120.
2008
|
|
| 2007
|
Racial/ethnic disparities in patient-reported nonsteroidal antiinflammatory drug (NSAID) risk awareness, patient-doctor NSAID risk communication, and NSAID risk behavior.
Arthritis and Rheumatism.
57:1539-1545.
2007
|
|
| 2007
|
Challenges in defining and improving osteoporosis quality of care.
Clinical and Experimental Rheumatology.
25.
2007
|
|
| 2007
|
Introduction.
Machine Learning.
25.
2007
|
|
| 2007
|
Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor α antagonists.
Arthritis and Rheumatism.
56:4226-4227.
2007
|
|
| 2007
|
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.
Annals of the Rheumatic Diseases.
66:1560-1567.
2007
|
|
| 2007
|
Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
New England Journal of Medicine.
357:2028-2039.
2007
|
|
| 2007
|
Treatment of acute gout-like arthritis in an emergency setting: Prednisolone versus indomethacin: Commentary.
Nature Reviews Rheumatology.
3:604-605.
2007
|
|
| 2007
|
Quality indicators for the care of osteoarthritis in vulnerable elders.
Journal of the American Geriatrics Society.
55.
2007
|
|
| 2007
|
Randomized Trial to Improve Fracture Prevention in Nursing Home Residents.
American Journal of Medicine.
120:886-892.
2007
|
|
| 2007
|
Mend the mind, but mind the bones! Balancing benefits and potential skeletal risks of serotonin reuptake inhibitors.
JAMA Internal Medicine.
167:1231-1232.
2007
|
|
| 2007
|
A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
Bone.
40:1238-1243.
2007
|
|
| 2007
|
Denosumab in postmenopausal women with low bone mineral density..
Current Rheumatology Reports.
9:48.
2007
|
|
| 2007
|
Effect of reproductive factors on rheumatoid arthritis.
International Journal of Clinical Rheumatology.
2:177-183.
2007
|
|
| 2007
|
Ibandronate injections in postmenopausal women with osteoporosis..
Current Rheumatology Reports.
9:47.
2007
|
|
| 2007
|
New directions in osteoporosis therapy: Intravenous ibandronate and denosumab.
Current Rheumatology Reports.
9:47-49.
2007
|
|
| 2007
|
Prevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis or recent fracture.
Osteoporosis International.
18:553-559.
2007
|
|
| 2007
|
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists.
Arthritis and Rheumatism.
56:1125-1133.
2007
|
|
| 2007
|
Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: A prospective randomized trial.
JAMA Internal Medicine.
167:591-596.
2007
|
|
| 2007
|
Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor α antagonists and disease-modifying antirheumatic drugs.
Arthritis and Rheumatism.
57:343-346.
2007
|
|
| 2007
|
Prevention and treatment of glucocorticoid-induced osteoporosis.
Current Osteoporosis Reports.
5:14-21.
2007
|
|
| 2007
|
Validity of gout diagnoses in administrative data.
Arthritis and Rheumatism.
57:103-108.
2007
|
|
| 2007
|
Challenges in defining and improving osteoporosis quality of care..
Clinical and Experimental Rheumatology.
25:142-146.
2007
|
|
| 2007
|
Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-α antagonists.
Rheumatology.
46:1688-1693.
2007
|
|
| 2006
|
Osteoporosis in the home health care setting: A window of opportunity?.
Arthritis and Rheumatism.
55:971-975.
2006
|
|
| 2006
|
Treatment of rheumatoid arthritis.
American Journal of Health-System Pharmacy.
63:2451-2465.
2006
|
|
| 2006
|
Improving the quality of clinical care for patients with osteoporosis
2006
|
|
| 2006
|
Introduction.
American Journal of Medicine.
119.
2006
|
|
| 2006
|
Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users.
Pharmacoepidemiology and Drug Safety.
15:710-718.
2006
|
|
| 2006
|
Sex differences in gout epidemiology: Evaluation and treatment.
Annals of the Rheumatic Diseases.
65:1368-1372.
2006
|
|
| 2006
|
Pathophysiology, clinical presentation and treatment of gout.
Drugs.
66:1547-1563.
2006
|
|
| 2006
|
Racial or ethnic differences in allele frequencies of sinqle-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis.
Annals of the Rheumatic Diseases.
65:1213-1218.
2006
|
|
| 2006
|
Smoking interacts with genetic risk factors in the development of rheumatoid arthritis among older Caucasian women.
Annals of the Rheumatic Diseases.
65:1163-1167.
2006
|
|
| 2006
|
Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.
Osteoporosis International.
17:1268-1274.
2006
|
|
| 2006
|
Osteoporotic fractures in older adults.
Best Practice and Research: Clinical Rheumatology.
20:695-706.
2006
|
|
| 2006
|
Trends in prevention of glucocorticoid-induced osteoporosis.
Journal of Rheumatology.
33:1651-1657.
2006
|
|
| 2006
|
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.
Journal of Clinical Endocrinology and Metabolism.
91:2631-2637.
2006
|
|
| 2006
|
Population-based assessment of adverse events associated with long-term glucocorticoid use.
Arthritis and Rheumatism.
55:420-426.
2006
|
|
| 2006
|
Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates?.
Reviews in Endocrine and Metabolic Disorders.
7:101-112.
2006
|
|
| 2006
|
Unbalanced regulation of over-the-counter analgesics: The lesser of two evils?.
Pharmacoepidemiology and Drug Safety.
15:410-411.
2006
|
|
| 2006
|
Is febuxostat a more effective treatment for hyperuricemia and gout than allopurinol? Commentary.
Nature Reviews Rheumatology.
2:240-241.
2006
|
|
| 2006
|
Agreement between medical record documentation and patient-reported use of nonsteroidal antiinflammatory drugs.
American Journal of Health-System Pharmacy.
63:744-747.
2006
|
|
| 2006
|
Epidemiology, risk factors, and lifestyle modifications for gout.
Arthritis Research and Therapy.
8.
2006
|
|
| 2006
|
Health-related quality of life among self-reported arthritis sufferers: Effects of race/ethnicity and residence.
Quality of Life Research.
15:451-460.
2006
|
|
| 2006
|
Prevention of osteoporosis associated with chronic glucocorticoid therapy: Commentary.
Journal of the American Medical Association.
295:1300-1303.
2006
|
|
| 2006
|
Medication errors with the use of allopurinol and colchicine: A retrospective study of a national, anonymous internet-accessible error reporting system.
Journal of Rheumatology.
33:562-566.
2006
|
|
| 2006
|
New insights into gout epidemiology.
Current Opinion in Rheumatology.
18:199-203.
2006
|
|
| 2006
|
Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial data.
Annals of the Rheumatic Diseases.
65:285-293.
2006
|
|
| 2006
|
Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophy.
AIDS Research and Human Retroviruses.
22:125-131.
2006
|
|
| 2006
|
Low-dose prednisolone in early rheumatoid arthritis.
Current Rheumatology Reports.
8:48-49.
2006
|
|
| 2006
|
The use of low-dose glucocorticoids for the treatment of early rheumatoid arthritis: What can we learn about bone effects of glucocorticoids from randomized controlled trials?.
Current Rheumatology Reports.
8:47-48.
2006
|
|
| 2006
|
Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions.
Pharmacoepidemiology and Drug Safety.
15:11-18.
2006
|
|
| 2006
|
Gout medication treatment patterns and adherence to standards of care from a managed care perspective.
Mayo Clinic Proceedings.
81:925-934.
2006
|
|
| 2006
|
Using a Modified Nominal Group Technique to Elicit Director of Nursing Input for an Osteoporosis Intervention
2006
|
|
| 2005
|
Fracture Reduction Affects Medicare Economics (FRAME): Impact of increased osteoporosis diagnosis and treatment.
Osteoporosis International.
16:1545-1557.
2005
|
|
| 2005
|
A group randomized trial to improve safe use of nonsteroidal anti-inflammatory drugs.
American Journal of Managed Care.
11:537-543.
2005
|
|
| 2005
|
Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients.
Arthritis and Rheumatism.
52:2485-2494.
2005
|
|
| 2005
|
Prevalence of osteoporosis and osteopenia among African Americans with early rheumatoid arthritis: The impact of ethnic-specific normative data.
Journal of the National Medical Association.
97:1155-1160.
2005
|
|
| 2005
|
Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: Results from the UK General Practice Research Database (GPRD).
Rheumatology.
44:1038-1042.
2005
|
|
| 2005
|
The cost of glucocorticoid-associated adverse events in rheumatoid arthritis.
Rheumatology.
44:781-788.
2005
|
|
| 2005
|
Racial disparities in the receipt of osteoporosis related healthcare among community-dwelling older women with arthritis and previous fracture.
Journal of Rheumatology.
32:870-875.
2005
|
|
| 2005
|
The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: Focus on the treatment of rheumatoid arthritis.
Scandinavian Journal of Rheumatology.
34:14-21.
2005
|
|
| 2005
|
Developments in glucocorticoid therapy.
Rheumatic Disease Clinics of North America.
31:1-17.
2005
|
|
| 2005
|
Gout epidemiology: Results from the UK General Practice Research Database, 1990-1999.
Annals of the Rheumatic Diseases.
64:267-272.
2005
|
|
| 2005
|
Barriers to providing osteoporosis care in skilled nursing facilities: Perceptions of medical directors and directors of nursing
2005
|
|
| 2005
|
Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care?.
Current Rheumatology Reports.
7:242-249.
2005
|
|
| 2005
|
Recent advances in the epidemiology of gout..
Current Rheumatology Reports.
7:235-241.
2005
|
|
| 2004
|
Glucocorticoid use in rheumatoid arthritis: Benefits, mechanisms, and risks.
Clinical and Experimental Rheumatology.
22.
2004
|
|
| 2004
|
Evaluating and improving the quality of care in rheumatic disease
2004
|
|
| 2004
|
Measuring quality in arthritis care: The arthritis foundation's quality indicator set for analgesics.
Arthritis and Rheumatism.
51:337-349.
2004
|
|
| 2004
|
Prevention of glucocorticoid-induced osteoporosis.
Southern Medical Journal.
97:555-558.
2004
|
|
| 2004
|
Measuring Quality in Arthritis Care: Methods for Developing the Arthritis Foundation's Quality Indicator Set.
Arthritis and Rheumatism.
51:193-202.
2004
|
|
| 2004
|
Quality of Care Indicators for Gout Management.
Arthritis and Rheumatism.
50:937-943.
2004
|
|
| 2004
|
Barriers to providing osteoporosis care in skilled nursing facilitities: Perceptions of Medical Directors and Directors of Nursing
2004
|
|
| 2004
|
Glucocorticoid use in rheumatoid arthritis: benefits, mechanisms, and risks..
Clinical and Experimental Rheumatology.
22:S77-S82.
2004
|
|
| 2004
|
Incidence of hip osteonecrosis among renal transplantation recipients: A prospective study.
Clinical Radiology.
59:431-438.
2004
|
|
| 2004
|
Vitamin D Intake Is Inversely Associated With Rheumatoid Arthritis: Results From the Iowa Women's Health Study.
Arthritis and Rheumatism.
50:72-77.
2004
|
|
| 2003
|
Nonsteroidal Antiinflammatory Drug Toxicity Monitoring and Safety Practices.
Journal of Rheumatology.
30:2680-2688.
2003
|
|
| 2003
|
Glucocorticoids in the treatment of early and late RA.
Annals of the Rheumatic Diseases.
62:1033-1037.
2003
|
|
| 2003
|
The association of race/ethnicity with the receipt of traditional and alternative arthritis-specific health care.
Medical Care.
41:1233-1239.
2003
|
|
| 2003
|
Osteoporosis: Evaluation and treatment.
Current women's health reports.
3:418-424.
2003
|
|
| 2003
|
The effects of physician specialty and patient comorbidities on the use and discontinuation of coxibs.
Arthritis and Rheumatism.
49:293-299.
2003
|
|
| 2003
|
Incidence of Nonvertebral Fractures in Relation to Time on Treatment and Bone Density in Glucocorticoid-Treated Patients: A Retrospective Approach
2003
|
|
| 2003
|
Health related quality of life in women with elderly onset rheumatoid arthritis.
Journal of Rheumatology.
30:952-957.
2003
|
|
| 2003
|
Racial Disparities in Osteoporosis Prevention in a Managed Care Population.
Southern Medical Journal.
96:445-451.
2003
|
|
| 2003
|
OMERACT 6 brings new perspectives to rheumatology measurement research.
Journal of Rheumatology.
30:639-641.
2003
|
|
| 2003
|
Antioxidant micronutrients and risk of rheumatoid arthritis in a cohort of older women.
American Journal of Epidemiology.
157:345-354.
2003
|
|
| 2003
|
The Use of Glucocorticoids in Arthritis – 20 Clinical Pearls.
The Journal of musculoskeletal medicine.
20:425-433.
2003
|
|
| 2003
|
Bone mineral density changes within six months of renal transplantation.
Transplantation.
75:49-54.
2003
|
|
| 2003
|
Bone mineral density changes within six months of renal transplantation..
Transplantation.
75:49-54.
2003
|
|
| 2003
|
Balancing bones and bucks among new glucocorticoid users.
Journal of Rheumatology.
30:1-3.
2003
|
|
| 2003
|
Estrogen and Other Female Reproductive Risk Factors Are Not Strongly Associated With the Development of Rheumatoid Arthritis in Elderly Women.
Seminars in Arthritis and Rheumatism.
33:72-82.
2003
|
|
| 2003
|
Glucocorticoid-induced osteoporosis.
Endocrinology and Metabolism Clinics of North America.
32:135-157.
2003
|
|
| 2002
|
Intolerance to caffeine may increase susceptibility to rheumatoid arthritis: Comment on the article by Mikuls et al [3] (multiple letters).
Arthritis and Rheumatism.
46:3104.
2002
|
|
| 2002
|
Health-related quality of life in Gulf War era military personnel.
American Journal of Epidemiology.
155:899-907.
2002
|
|
| 2002
|
Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women: Results from the Iowa Women's Health Study.
American Journal of Medicine.
112:465-471.
2002
|
|
| 2002
|
Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: Results from the Iowa women's health study.
Arthritis and Rheumatism.
46:83-91.
2002
|
|
| 2002
|
Blood transfusion, alcohol use, and anthropometric risk factors for rheumatoid arthritis in older women.
Journal of Rheumatology.
29:246-254.
2002
|
|
| 2002
|
Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: results from the Iowa Women's Health Study..
Arthritis and Rheumatism.
46:83-91.
2002
|
|
| 2002
|
Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: A six-month, double-blind, randomized, dose-ranging study.
Arthritis and Rheumatism.
46:2020-2028.
2002
|
|
| 2002
|
Glucocorticoid therapy for arthritis: Overcoming the problems.
Drug Benefit Trends.
14:39-43+52.
2002
|
|
| 2002
|
Glucocorticoid use in rheumatoid arthritis..
Current Rheumatology Reports.
4:218-225.
2002
|
|
| 2002
|
Metabolic bone disease.
Current Opinion in Rheumatology.
14:404-405.
2002
|
|
| 2002
|
Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: Results from the Iowa Women's Health Study.
Annals of the Rheumatic Diseases.
61:994-999.
2002
|
|
| 2001
|
Protein-losing enteropathy in a young African-American woman with abdominal pain, diarrhea and hydronephrosis.
Lupus.
10:835-840.
2001
|
|
| 2001
|
Samarium-153-EDTMP in the treatment of refractory rheumatoid arthritis.
Scandinavian Journal of Rheumatology.
30:356-359.
2001
|
|
| 2001
|
Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort.
Journal of Rheumatology.
28:1298-1305.
2001
|
|
| 2001
|
Comorbidity in rheumatoid arthritis.
Rheumatic Disease Clinics of North America.
27:283-303.
2001
|
|
| 2001
|
Preferences for fractures and other glucocorticoid-associated adverse effects among rheumatoid arthritis patients.
Medical Decision Making.
21:122-132.
2001
|
|
| 2001
|
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 Update: American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis.
Arthritis and Rheumatism.
44:1496-1503.
2001
|
|
| 2001
|
Resolved: Low-dose glucocorticoids are neither safe nor effective for the long-term treatment of rheumatoid arthritis.
Arthritis and Rheumatism.
45:468-471.
2001
|
|
| 2001
|
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial.
Arthritis and Rheumatism.
44:202-211.
2001
|
|
| 2001
|
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial..
Arthritis and Rheumatism.
44:202-211.
2001
|
|
| 2001
|
Use of complementary and alternative medicine by older patients with arthritis: A population-based study.
Arthritis and Rheumatism.
45:398-403.
2001
|
|
| 2000
|
Erratum: Rofecoxib: A viewpoint by R.H. Hunt. Guest commentary (Drugs (1999) 58 (3) (506-507)).
Drugs.
59:179.
2000
|
|
| 2000
|
Practice pattern variation among internal medicine specialists in the prevention of glucocorticoid-induced osteoporosis
2000
|
|
| 2000
|
Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: A 6-week and a 1-year trial in patients with osteoarthritis.
Archives of family medicine.
9:1124-1134.
2000
|
|
| 1999
|
Influenza and Pneumococcal Vaccine Receipt in Older Persons with Chronic Disease: A Population-Based Study.
Medical Care.
37:502-509.
1999
|
|
| 1999
|
Epidemiology of glucocorticoid-induced osteoporosis concepts and controversies
1999
|
|
| 1999
|
Rofecoxib. Viewpoints.
Drugs.
58:506.
1999
|
|
| 1998
|
Nonsteroidal anti-inflammatory drugs and cognitive function. Do they have a beneficial or deleterious effect?.
Drug Safety.
19:427-433.
1998
|
|
| 1998
|
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis.
New England Journal of Medicine.
339:292-299.
1998
|
|
| 1998
|
Moderate-term, low-dose corticosteroids for rheumatoid arthritis
1998
|
|
| 1998
|
Point of view.
Spine.
23:838.
1998
|
|
| 1998
|
Arthritis health service utilization among the elderly: The role of urban-rural residence and other utilization factors.
Arthritis and Rheumatism.
11:177-185.
1998
|
|
| 1998
|
Arthritis health service utilization among the elderly: The role of urban-rural residence and other utilization factors.
Arthritis and Rheumatism.
11:177-185.
1998
|
|
| 1998
|
Variation in Tertiary Prevention and Health Service Utilization among the Elderly: The Role of Urban-Rural Residence and Supplemental Insurance.
Medical Care.
36:965-976.
1998
|
|
| 1997
|
Low-dose corticosteroid therapy in rheumatoid arthritis: Balancing the evidence.
American Journal of Medicine.
103.
1997
|
|
| 1997
|
Low-dose corticosteroid therapy in rheumatoid arthritis: balancing the evidence..
American Journal of Medicine.
103:31S-39S.
1997
|
|
| 1997
|
Health services research.
Current Opinion in Rheumatology.
9:118-125.
1997
|
|
| 1997
|
Mixed connective tissue disease and radiation toxicity: A case report.
Cancer.
79:612-618.
1997
|
|
| 1997
|
Cigarette smoking and rheumatoid arthritis severity.
Annals of the Rheumatic Diseases.
56:463-469.
1997
|
|
| 1996
|
Low-dose corticosteroids in rheumatoid arthritis: A meta-analysis of their moderate-term effectiveness.
Arthritis and Rheumatism.
39:1818-1825.
1996
|
|
| 1996
|
Methotrexate patient education: A quality improvement study.
Arthritis and Rheumatism.
9:216-222.
1996
|
|
| 1996
|
Methotrexate patient education: A quality improvement study.
Arthritis and Rheumatism.
9:216-222.
1996
|
|
| 1996
|
Rheumatoid arthritis lung disease: Determinants of radiographic and physiologic abnormalities.
Arthritis and Rheumatism.
39:1711-1719.
1996
|
|
| 1996
|
The foot function index for measuring rheumatoid arthritis pain: Evaluating side-to-side reliability.
Foot and Ankle International.
17:506-510.
1996
|
|
| 1995
|
Nonsteroidal antiinflammatory drugs and cognitive decline in the elderly.
Journal of Rheumatology.
22:2142-2147.
1995
|
|
| 1995
|
Serious adverse events with low-dose, long-term corticosteroid therapy in rheumatoid arthritis.
American Journal of Medicine.
99:692-693.
1995
|
|
| 1995
|
The reply.
American Journal of Medicine.
99:693-694.
1995
|
|
| 1994
|
Nonsteroidal anti-inflammatory drugs. Balancing benefits and risks..
Spine.
19:1530-1534.
1994
|
|
| 1994
|
Low dose long-term corticosteroid therapy in rheumatoid arthritis : an analysis of serious adverse events
1994
|
|
| 1994
|
Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events.
American Journal of Medicine.
96:115-123.
1994
|
|
| 1994
|
Spine update nonsteroidal anti-inflammatory drugs balancing benefits and risks.
Spine.
19:1530-1534.
1994
|
|
| 1993
|
Parvovirus Bl9-specific DNA in bone marrow from B19 arthropathy patients: Evidence for B19 virus persistence.
Journal of Infectious Diseases.
167:744-748.
1993
|
|
| 1992
|
Subcutaneous pancreatic fat necrosis associated with acute arthritis.
Journal of Rheumatology.
19:630-632.
1992
|
|
| 1990
|
An eosinophilia-myalgia syndrome associated with an L-tryptophan containing product.
Journal of Rheumatology.
17:1551-1553.
1990
|
|
| 1989
|
Infectious Diarrhea Secondary to Enteromonas hominis.
American Journal of Gastroenterology.
84:1313-1314.
1989
|
|
